A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumorsAnticipate ...

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer ...

With a median follow-up of over 14 months, ADVC001, a novel Lead-212 PSMA therapy, continues to show favorable tolerability with no new safety signals in metastatic androgen pathway ...

Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NETDurable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...

First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy ...

A near-infrared fluorescent choline kinase α inhibitor, JAS239, was used to identify tumors in canine patients.

By turning a patient's own immune cells into stronger cancer-fighting cells, CAR T-cell therapy has transformed how some ...

A new review reveals that sugar chains attached to death receptors act as molecular checkpoints that determine whether cells ...

A new opinion article argues that inflammation may be the missing link explaining both the potential suicide risk and the ...